Clinical Trial Update: An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands [Phase 1]

View source ↗

Summary

Phase 1 open-label PET study in healthy male subjects to evaluate brain DAT and SERT occupancy, pharmacokinetics, and safety after single oral doses of GSK13607…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder

Drugs mentioned

• GSK1360707

Snippet

Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder | Phase 1 | Status: COMPLETED